Advertisement
U.S. markets close in 2 hours

Johnson & Johnson (JNJ)

NYSE - Nasdaq Real Time Price. Currency in USD
158.49+0.53 (+0.34%)
As of 02:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close157.96
Open158.20
Bid158.42 x 800
Ask158.45 x 1000
Day's Range158.11 - 159.14
52 Week Range144.95 - 175.97
Volume1,994,024
Avg. Volume7,131,095
Market Cap381.926B
Beta (5Y Monthly)0.53
PE Ratio (TTM)30.48
EPS (TTM)5.20
Earnings DateApr 16, 2024
Forward Dividend & Yield4.76 (3.01%)
Ex-Dividend DateFeb 16, 2024
1y Target Est162.68
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JNJ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Johnson & Johnson
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    10 days agoArgus Research
View more
  • Zacks

    Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

    Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

  • Motley Fool

    3 Dividend Stocks That Are Likely to Raise Their Payouts in April

    Dividend increases should soon be coming from these stocks, but be careful -- it doesn't mean all of them are great buys.

  • Reuters

    UPDATE 3-J&J can contest evidence linking its talc to cancer, US judge rules

    Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer. Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016.